| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1635088/0001635088-26-000038.txt","as_of":"2026-04-21T03:09:54.871544+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1635088/0001635088-26-000038.txt","company":"Roivant Sciences Ltd.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1635088/0001635088-26-000038.txt","article_chars":2030,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_bd490222a49e5233","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1635088/0001635088-26-000038.txt","content_type":"text/plain","enriched_at":"2026-04-21T10:44:50.605378+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1635088/0001635088-26-000038.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1635088/0001635088-26-000038.txt","source_event_id":"evt_0d0e7b9d1c2e","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"84b4e8599be613ba","kind":"sec_filing","published_at":"20260420","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2026-04-20","2026-04-21T03:09:54.871544+00:00","2026-04-16"],"entities":[{"asset_class":"equity","name":"Roivant Sciences Ltd.","relevance":"high","symbol":"ROIV","type":"issuer"},{"asset_class":"equity","name":"Matthew Gline","relevance":"high","symbol":"","type":"reporting_owner"},{"asset_class":"equity","name":"Jo Chen","relevance":"low","symbol":"","type":"attorney_in_fact"}],"event_type":"other","information_gaps":["No prior known state is provided in the signal, so the specific 'delta vs prior' change cannot be determined from the provided text alone.","The filing text excerpt does not explicitly state whether there were any purchases or other transactions besides the reported sale.","The excerpt does not provide the total dollar value of the transaction(s)."],"key_facts":["SEC filing type: Form 4.","Issuer: Roivant Sciences Ltd.","Issuer ticker/symbol shown in filing values: ROIV.","Reporting person: Matthew Gline (listed as CEO).","Conformed period of report (transaction date): 2026-04-16.","Filed as of date: 2026-04-20.","Reported transaction: sale of 289,774 common shares.","Weighted average price reported in column 4: $29.16.","Shares were sold in multiple transactions at prices ranging from $28.98 to $29.36 (inclusive).","Undertaking included to provide full information on number of shares sold at each separate price within the range upon request."],"numeric_claims":[{"label":"shares_sold","value":"289,774"},{"label":"weighted_average_price_usd","value":"29.16"},{"label":"min_transaction_price_usd","value":"28.98"},{"label":"max_transaction_price_usd","value":"29.36"}],"primary_claim":"On 2026-04-16, Matthew Gline sold 289,774 shares of Roivant Sciences Ltd. common stock at a weighted average price of $29.16 (with transaction prices ranging from $28.98 to $29.36).","relevance_score":0.55,"sentiment":"neutral","source_quality":"medium","summary":"Roivant Sciences Ltd. (ROIV) filed a Form 4 on 2026-04-20 reporting that reporting person Matthew Gline sold 289,774 common shares on 2026-04-16 at a weighted average price of $29.16.","topics":["SEC Form 4","insider trading","common shares sale","weighted average price","transaction price range"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 Roivant Sciences Ltd. \u00b7 Filed 20260420","ticker":"ROIV","tickers":["ROIV"],"title":"ROIV filed 4","url":"https://www.sec.gov/Archives/edgar/data/1635088/0001635088-26-000038.txt"}... |